These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 36754491)

  • 1. Nonalcoholic Fatty Liver Disease.
    Isaacs S
    Endocrinol Metab Clin North Am; 2023 Mar; 52(1):149-164. PubMed ID: 36754491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease.
    Makri E; Goulas A; Polyzos SA
    Arch Med Res; 2021 Jan; 52(1):25-37. PubMed ID: 33334622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic fatty liver disease should be considered for treatment allocation in standard management algorithms for type 2 diabetes.
    Kuchay MS; Choudhary NS; Mishra SK; Misra A
    Diabetes Metab Syndr; 2020; 14(6):2233-2239. PubMed ID: 33336648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
    Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Approach to the Patient With Nonalcoholic Fatty Liver Disease.
    Belfort-DeAguiar R; Lomonaco R; Cusi K
    J Clin Endocrinol Metab; 2023 Jan; 108(2):483-495. PubMed ID: 36305273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
    Zhou JH; Cai JJ; She ZG; Li HL
    World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of diabetologists in the management of nonalcoholic fatty liver disease: Primary prevention and screening/management of fibrosis and cirrhosis.
    Kuchay MS; Misra A
    Diabetes Metab Syndr; 2022 Mar; 16(3):102446. PubMed ID: 35259705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients With Type-2 Diabetes With Biopsy-proven Nonalcoholic Fatty Liver Disease.
    Singh A; Gosai F; Siddiqui MT; Gupta M; Lopez R; Lawitz E; Poordad F; Carey W; McCullough A; Alkhouri N
    J Clin Gastroenterol; 2020; 54(10):891-897. PubMed ID: 32168133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonalcoholic Steatohepatitis: A Review.
    Sheka AC; Adeyi O; Thompson J; Hameed B; Crawford PA; Ikramuddin S
    JAMA; 2020 Mar; 323(12):1175-1183. PubMed ID: 32207804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    ; ;
    Obes Facts; 2024; 17(4):374-444. PubMed ID: 38852583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
    Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
    Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.
    Bazick J; Donithan M; Neuschwander-Tetri BA; Kleiner D; Brunt EM; Wilson L; Doo E; Lavine J; Tonascia J; Loomba R
    Diabetes Care; 2015 Jul; 38(7):1347-55. PubMed ID: 25887357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CROATIAN GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE.
    Virović Jukić L; Grgurević I; Mikolašević I; Filipec Kanižaj T; Milić S; Mrzljak A; Premužić M; Hrstić I; Knežević-Štromar I; Ljubičić N; Ostojić R; Stojsavljević Shapeski S; Amerl-Šakić V; Marković NB; Rađa M; Soldo D; Sobočan N; Lalovac M; Puljiz Ž; Podrug K; Ladić D
    Acta Clin Croat; 2021 Dec; 60(Suppl 2):36-52. PubMed ID: 35528151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
    Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of nonalcoholic fatty liver disease (NAFLD) in severe obesity using noninvasive tests and imaging techniques.
    Theel W; Boxma-de Klerk BM; Dirksmeier-Harinck F; van Rossum EFC; Kanhai DA; Apers J; van Dalen BM; de Knegt RJ; Holleboom AG; Tushuizen ME; Grobbee DE; Wiebolt J; Castro Cabezas M
    Obes Rev; 2022 Aug; 23(8):e13481. PubMed ID: 35692179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-invasive diagnosis of nonalcoholic fatty liver disease in patients with type 2 diabetes.
    Alhinai A; Patel K; Fonseca VA; Sebastiani G
    J Diabetes Complications; 2021 Sep; 35(9):107978. PubMed ID: 34183247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography.
    Tsai E; Lee TP
    Clin Liver Dis; 2018 Feb; 22(1):73-92. PubMed ID: 29128062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role Bariatric Surgery and Endobariatric Therapies in Nonalcoholic Steatohepatitis.
    Yeoh A; Wong R; Singal AK
    Clin Liver Dis; 2023 May; 27(2):413-427. PubMed ID: 37024216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes.
    Bril F; McPhaul MJ; Caulfield MP; Clark VC; Soldevilla-Pico C; Firpi-Morell RJ; Lai J; Shiffman D; Rowland CM; Cusi K
    Diabetes Care; 2020 Feb; 43(2):290-297. PubMed ID: 31604692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments.
    Roeb E; Geier A
    Z Gastroenterol; 2019 Apr; 57(4):508-517. PubMed ID: 30965381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.